Chilean RSV Vaccine Advances to Phase 2 Clinical Trials in Europe, Targeting Elderly Population
Key Insights
A groundbreaking RSV vaccine developed by Chilean researchers at UC Chile has received approval for Phase 2 clinical trials in Europe, focusing on adults over 60 years old.
The vaccine demonstrated promising safety and efficacy results in preclinical studies and Phase 1 trials, marking a significant milestone for Chilean scientific research in global healthcare.
RSV causes approximately 3.4 million hospitalizations worldwide annually and affects nearly 5% of infants and children under 5 with acute lower respiratory infections.
European health regulators have greenlit Phase 2 clinical trials for a novel Respiratory Syncytial Virus (search) (RSV) vaccine developed by Chilean researchers, marking a significant advancement in the fight against a major respiratory pathogen. The vaccine, developed under the leadership of Dr. Alexis Kalergis at Pontificia Universidad Católica de Chile (UC Chile), will target adults over 60, a population particularly vulnerable to severe RSV complications.
Clinical Trial Design and Objectives
The Phase 2 trial aims to validate the vaccine's safety profile and immunogenicity in a broader population cohort. This crucial stage follows successful preclinical studies and Phase 1 trials conducted in Chile with healthy young adults, which demonstrated promising safety and efficacy outcomes.
"This approach will not only deepen the evaluation of the formula but also gather relevant information that supports its potential implementation as an effective tool to protect the most vulnerable populations," explains Dr. Kalergis, who also serves as Director of the Millennium Institute of Immunology and Immunotherapy (IMII).
Global Health Impact and Disease Burden
RSV represents a significant global health challenge, particularly affecting vulnerable populations at both ends of the age spectrum. Current epidemiological data reveals that RSV is responsible for:
- 3.4 million hospitalizations worldwide annually
- Nearly 5% of acute lower respiratory infection episodes in children under 5
- Approximately 5,000 hospitalizations annually in Chile during non-COVID years
Research Collaboration and Future Prospects
The development of this vaccine represents a collaborative effort between UC Chile and the Angelini Group (search), supported by both public and private funding. Dr. Pablo González, professor at the Faculty of Biological Sciences and IMII researcher, outlines the next steps: "We hope that the results from this Phase 2 trial will be favorable and allow us to move forward to a Phase 3 clinical trial, in which a larger number of participants will be recruited to assess its efficacy against natural exposure to the virus."
International Recognition and Strategic Partnerships
The European trial authorization represents a significant validation of Chilean scientific capabilities. Dr. Susan Bueno, UC Chile academic and scientific director of the study, emphasizes that this advancement "represents not only a milestone for Chilean science but also highlights the impact of international collaboration in medical research."
Dr. Hernán Peñaloza of UC Chile adds that European countries, with their advanced infrastructure and extensive experience in clinical trials, serve as strategic partners in validating this vaccine's potential to protect vulnerable populations against RSV.
The successful progression to Phase 2 trials positions this Chilean-developed vaccine as a promising candidate in the global effort to combat RSV infections, potentially offering new protection for at-risk populations worldwide.